Nuvectis Pharma (NVCT) Expected to Announce Earnings on Tuesday

Key Points

• Nuvectis Pharma (NVCT) is set to announce its Q2 2025 earnings on August 5th, with analysts predicting earnings of ($0.25) per share.
• Insider Marlio Charles Mosseri recently purchased over 5,600 shares of NVCT stock for around $44,768, increasing their ownership stake in the company.
• Institutional investors hold approximately 96.77% of Nuvectis Pharma's stock, with Goldman Sachs recently acquiring a new position valued at about $446,000.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.03. On average, analysts expect Nuvectis Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nuvectis Pharma Price Performance

NASDAQ:NVCT traded down $0.17 during mid-day trading on Friday, hitting $6.80. The company's stock had a trading volume of 71,019 shares, compared to its average volume of 145,102. Nuvectis Pharma has a 1 year low of $4.44 and a 1 year high of $11.80. The stock has a market cap of $141.95 million, a price-to-earnings ratio of -6.01 and a beta of -0.25. The business's fifty day moving average is $8.32 and its two-hundred day moving average is $8.19.

Insider Buying and Selling at Nuvectis Pharma

In related news, major shareholder Marlio Charles Mosseri purchased 28,043 shares of Nuvectis Pharma stock in a transaction that occurred on Wednesday, June 18th. The stock was purchased at an average price of $8.05 per share, for a total transaction of $225,746.15. Following the transaction, the insider directly owned 2,976,203 shares in the company, valued at approximately $23,958,434.15. This trade represents a 0.95% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In the last three months, insiders have bought 75,306 shares of company stock worth $615,781. 30.52% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nuvectis Pharma stock. Goldman Sachs Group Inc. purchased a new position in shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 45,608 shares of the company's stock, valued at approximately $446,000. Goldman Sachs Group Inc. owned about 0.22% of Nuvectis Pharma as of its most recent SEC filing. Hedge funds and other institutional investors own 96.77% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on NVCT shares. Wall Street Zen lowered shares of Nuvectis Pharma from a "hold" rating to a "sell" rating in a report on Sunday, June 29th. HC Wainwright reissued a "buy" rating and set a $15.00 target price (up from $11.00) on shares of Nuvectis Pharma in a research note on Wednesday, April 30th.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.